Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationTransplantation, AutologousTransplantation, HomologousTransplantation ConditioningHematopoietic Stem Cell MobilizationHematologic NeoplasmsStem Cell TransplantationHematopoietic Stem CellsMelphalanAntigens, CD34Granulocyte Colony-Stimulating FactorCombined Modality TherapyLeukapheresisGraft vs Host DiseaseBlood Component RemovalMultiple MyelomaCyclophosphamideStem CellsTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBusulfanMyeloablative AgonistsGraft SurvivalLymphoma, Non-HodgkinEtoposideThiotepaRemission InductionAntineoplastic Agents, AlkylatingRecurrenceHematopoiesisTissue DonorsCytophagocytosisTransplantation ChimeraCarmustineSalvage TherapyHistocompatibility TestingIfosfamideRetrospective StudiesAmyloidosisVincristineCord Blood Stem Cell TransplantationHodgkin DiseaseDisease-Free SurvivalCytarabineImmunosuppressive AgentsNeoplasmsSurvival RateWhole-Body IrradiationLeukemiaTime FactorsHistocompatibilitySurvival AnalysisInfectionTransplantationCytomegalovirus InfectionsLymphoma, T-CellFollow-Up StudiesDoxorubicinAnemia, AplasticPOEMS SyndromePlatelet CountStem Cell NicheLeukemia, Myeloid, AcutePrednisoneVidarabineCarboplatinTransplantation, IsogeneicDexamethasoneImmunocompromised HostCell DifferentiationFatal OutcomeAntineoplastic AgentsBone Marrow PurgingAdult Stem CellsBone MarrowProspective StudiesBlood Cell CountHLA AntigensHepatic Veno-Occlusive DiseaseRecombinant ProteinsGraft vs Leukemia EffectLymphomaFlow CytometryOpportunistic InfectionsEmbryonic Stem CellsBlood CellsFeasibility StudiesMyelodysplastic SyndromesBone Marrow CellsMesenchymal Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematologic DiseasesCells, CulturedFetal BloodLymphocyte DepletionImmunophenotypingKidney TransplantationCyclosporine